



Pulmonary Hypertension Drug Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-26	122	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Pulmonary Hypertension Drug market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Pulmonary Hypertension Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Pulmonary Hypertension Drug is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Pulmonary Hypertension Drug is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Pulmonary Hypertension Drug include Biolab Sanus Farmaceutica Ltda., Hanmi Pharmaceuticals, Co. Ltd., Ikaria Inc., Proreo Pharma AG, Vectura Group plc, Vicore Pharma AB, Bayer AG and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Pulmonary Hypertension Drug market in terms of revenue (US\$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pulmonary Hypertension Drug Market by Company

Biolab Sanus Farmaceutica Ltda.

Hanmi Pharmaceuticals, Co. Ltd.

Ikaria Inc.
Proreo Pharma AG
Vectura Group plc
Vicore Pharma AB
Bayer AG
Sanofi

Pulmonary Hypertension Drug Segment by Type

IK-3001
Riociguat
Sildenafil Citrate IMD
SAR-407899
IK-7002
Others

Pulmonary Hypertension Drug Segment by Application

Clinic
Hospital
Others

Pulmonary Hypertension Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Hypertension Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Hypertension Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Hypertension Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Pulmonary Hypertension Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Pulmonary Hypertension Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Pulmonary Hypertension Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Pulmonary Hypertension Drug Market Size (2021-2032)
 - 2.2.2 Global Pulmonary Hypertension Drug Sales (2021-2032)
 - 2.2.3 Global Pulmonary Hypertension Drug Market Average Price (2021-2032)
- 2.3 Pulmonary Hypertension Drug by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 IK-3001
 - 2.3.3 Riociguat
 - 2.3.4 Sildenafil Citrate IMD
 - 2.3.5 SAR-407899
 - 2.3.6 IK-7002
 - 2.3.7 Others
- 2.4 Pulmonary Hypertension Drug by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Clinic
 - 2.4.3 Hospital
 - 2.4.4 Others

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Pulmonary Hypertension Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pulmonary Hypertension Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Pulmonary Hypertension Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Pulmonary Hypertension Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Pulmonary Hypertension Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pulmonary Hypertension Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pulmonary Hypertension Drug, Product Type & Application
- 3.8 Global Manufacturers of Pulmonary Hypertension Drug, Established Date
- 3.9 Global Pulmonary Hypertension Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Biolab Sanus Farmaceutica Ltda.
 - 4.1.1 Biolab Sanus Farmaceutica Ltda. Company Information
 - 4.1.2 Biolab Sanus Farmaceutica Ltda. Business Overview
 - 4.1.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)

- 4.1.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio
- 4.1.5 Biolab Sanus Farmaceutica Ltda. Recent Developments
- 4.2 Hanmi Pharmaceuticals, Co. Ltd.
 - 4.2.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
 - 4.2.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
 - 4.2.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.2.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio
 - 4.2.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
- 4.3 Icaria Inc.
 - 4.3.1 Icaria Inc. Company Information
 - 4.3.2 Icaria Inc. Business Overview
 - 4.3.3 Icaria Inc. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 Icaria Inc. Pulmonary Hypertension Drug Product Portfolio
 - 4.3.5 Icaria Inc. Recent Developments
- 4.4 Proreo Pharma AG
 - 4.4.1 Proreo Pharma AG Company Information
 - 4.4.2 Proreo Pharma AG Business Overview
 - 4.4.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio
 - 4.4.5 Proreo Pharma AG Recent Developments
- 4.5 Vectura Group plc
 - 4.5.1 Vectura Group plc Company Information
 - 4.5.2 Vectura Group plc Business Overview
 - 4.5.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 Vectura Group plc Pulmonary Hypertension Drug Product Portfolio
 - 4.5.5 Vectura Group plc Recent Developments
- 4.6 Vicore Pharma AB
 - 4.6.1 Vicore Pharma AB Company Information
 - 4.6.2 Vicore Pharma AB Business Overview
 - 4.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio
 - 4.6.5 Vicore Pharma AB Recent Developments
- 4.7 Bayer AG
 - 4.7.1 Bayer AG Company Information
 - 4.7.2 Bayer AG Business Overview
 - 4.7.3 Bayer AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 Bayer AG Pulmonary Hypertension Drug Product Portfolio
 - 4.7.5 Bayer AG Recent Developments
- 4.8 Sanofi
 - 4.8.1 Sanofi Company Information
 - 4.8.2 Sanofi Business Overview
 - 4.8.3 Sanofi Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 Sanofi Pulmonary Hypertension Drug Product Portfolio
 - 4.8.5 Sanofi Recent Developments

5 Global Pulmonary Hypertension Drug Market Scenario by Region

- 5.1 Global Pulmonary Hypertension Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pulmonary Hypertension Drug Sales by Region: 2021-2032
 - 5.2.1 Global Pulmonary Hypertension Drug Sales by Region: 2021-2026

- 5.2.2 Global Pulmonary Hypertension Drug Sales by Region: 2027-2032
- 5.3 Global Pulmonary Hypertension Drug Revenue by Region: 2021-2032
 - 5.3.1 Global Pulmonary Hypertension Drug Revenue by Region: 2021-2026
 - 5.3.2 Global Pulmonary Hypertension Drug Revenue by Region: 2027-2032
- 5.4 North America Pulmonary Hypertension Drug Market Facts & Figures by Country
 - 5.4.1 North America Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Pulmonary Hypertension Drug Sales by Country (2021-2032)
 - 5.4.3 North America Pulmonary Hypertension Drug Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
 - 5.4.6 Mexico
- 5.5 Europe Pulmonary Hypertension Drug Market Facts & Figures by Country
 - 5.5.1 Europe Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.5.2 Europe Pulmonary Hypertension Drug Sales by Country (2021-2032)
 - 5.5.3 Europe Pulmonary Hypertension Drug Revenue by Country (2021-2032)
 - 5.5.4 Germany
 - 5.5.5 France
 - 5.5.6 U.K.
 - 5.5.7 Italy
 - 5.5.8 Russia
 - 5.5.9 Spain
 - 5.5.10 Netherlands
 - 5.5.11 Switzerland
 - 5.5.12 Sweden
 - 5.5.13 Poland
- 5.6 Asia Pacific Pulmonary Hypertension Drug Market Facts & Figures by Country
 - 5.6.1 Asia Pacific Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.6.2 Asia Pacific Pulmonary Hypertension Drug Sales by Country (2021-2032)
 - 5.6.3 Asia Pacific Pulmonary Hypertension Drug Revenue by Country (2021-2032)
 - 5.6.4 China
 - 5.6.5 Japan
 - 5.6.6 South Korea
 - 5.6.7 India
 - 5.6.8 Australia
 - 5.6.9 Taiwan
 - 5.6.10 Southeast Asia
- 5.7 South America Pulmonary Hypertension Drug Market Facts & Figures by Country
 - 5.7.1 South America Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.7.2 South America Pulmonary Hypertension Drug Sales by Country (2021-2032)
 - 5.7.3 South America Pulmonary Hypertension Drug Revenue by Country (2021-2032)
 - 5.7.4 Brazil
 - 5.7.5 Argentina
 - 5.7.6 Chile
- 5.8 Middle East and Africa Pulmonary Hypertension Drug Market Facts & Figures by Country
 - 5.8.1 Middle East and Africa Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.8.2 Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2021-2032)
 - 5.8.3 Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2021-2032)
 - 5.8.4 Egypt

- 5.8.5 South Africa
 - 5.8.6 Israel
 - 5.8.7 Türkiye
 - 5.8.8 GCC Countries
-

6 Segment by Type

- 6.1 Global Pulmonary Hypertension Drug Sales by Type (2021-2032)
 - 6.1.1 Global Pulmonary Hypertension Drug Sales by Type (2021-2032) & (W Units)
 - 6.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Type (2021-2032)
 - 6.2 Global Pulmonary Hypertension Drug Revenue by Type (2021-2032)
 - 6.2.1 Global Pulmonary Hypertension Drug Sales by Type (2021-2032) & (US\$ Million)
 - 6.2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Type (2021-2032)
 - 6.3 Global Pulmonary Hypertension Drug Price by Type (2021-2032)
-

7 Segment by Application

- 7.1 Global Pulmonary Hypertension Drug Sales by Application (2021-2032)
 - 7.1.1 Global Pulmonary Hypertension Drug Sales by Application (2021-2032) & (W Units)
 - 7.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Application (2021-2032)
 - 7.2 Global Pulmonary Hypertension Drug Revenue by Application (2021-2032)
 - 7.2.1 Global Pulmonary Hypertension Drug Sales by Application (2021-2032) & (US\$ Million)
 - 7.2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Application (2021-2032)
 - 7.3 Global Pulmonary Hypertension Drug Price by Application (2021-2032)
-

8 Value Chain and Sales Channels Analysis of the Market

- 8.1 Pulmonary Hypertension Drug Value Chain Analysis
 - 8.1.1 Pulmonary Hypertension Drug Key Raw Materials
 - 8.1.2 Raw Materials Key Suppliers
 - 8.1.3 Pulmonary Hypertension Drug Production Mode & Process
 - 8.2 Pulmonary Hypertension Drug Sales Channels Analysis
 - 8.2.1 Direct Comparison with Distribution Share
 - 8.2.2 Pulmonary Hypertension Drug Distributors
 - 8.2.3 Pulmonary Hypertension Drug Customers
-

9 Global Pulmonary Hypertension Drug Analyzing Market Dynamics

- 9.1 Pulmonary Hypertension Drug Industry Trends
 - 9.2 Pulmonary Hypertension Drug Industry Drivers
 - 9.3 Pulmonary Hypertension Drug Industry Opportunities and Challenges
 - 9.4 Pulmonary Hypertension Drug Industry Restraints
-

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Pulmonary Hypertension Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Pulmonary Hypertension Drug Sales (W Units) of Manufacturers (2021-2026)
- Table 7: Global Pulmonary Hypertension Drug Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Pulmonary Hypertension Drug Revenue of Manufacturers (2021-2026)
- Table 9: Global Pulmonary Hypertension Drug Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Pulmonary Hypertension Drug Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Pulmonary Hypertension Drug Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Pulmonary Hypertension Drug, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Pulmonary Hypertension Drug, Product Type & Application
- Table 14: Global Pulmonary Hypertension Drug Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Pulmonary Hypertension Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Biolab Sanus Farmaceutica Ltda. Company Information
- Table 19: Biolab Sanus Farmaceutica Ltda. Business Overview
- Table 20: Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio
- Table 22: Biolab Sanus Farmaceutica Ltda. Recent Developments
- Table 23: Hanmi Pharmaceuticals, Co. Ltd. Company Information
- Table 24: Hanmi Pharmaceuticals, Co. Ltd. Business Overview
- Table 25: Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio
- Table 27: Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
- Table 28: Ikaria Inc. Company Information
- Table 29: Ikaria Inc. Business Overview
- Table 30: Ikaria Inc. Pulmonary Hypertension Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio
- Table 32: Ikaria Inc. Recent Developments
- Table 33: Proreo Pharma AG Company Information
- Table 34: Proreo Pharma AG Business Overview
- Table 35: Proreo Pharma AG Pulmonary Hypertension Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio
- Table 37: Proreo Pharma AG Recent Developments
- Table 38: Vectura Group plc Company Information
- Table 39: Vectura Group plc Business Overview
- Table 40: Vectura Group plc Pulmonary Hypertension Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Vectura Group plc Pulmonary Hypertension Drug Product Portfolio
- Table 42: Vectura Group plc Recent Developments
- Table 43: Vicore Pharma AB Company Information
- Table 44: Vicore Pharma AB Business Overview
- Table 45: Vicore Pharma AB Pulmonary Hypertension Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 46: Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio
- Table 47: Vicore Pharma AB Recent Developments

- Table 48: Bayer AG Company Information
- Table 49: Bayer AG Business Overview
- Table 50: Bayer AG Pulmonary Hypertension Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 51: Bayer AG Pulmonary Hypertension Drug Product Portfolio
- Table 52: Bayer AG Recent Developments
- Table 53: Sanofi Company Information
- Table 54: Sanofi Business Overview
- Table 55: Sanofi Pulmonary Hypertension Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 56: Sanofi Pulmonary Hypertension Drug Product Portfolio
- Table 57: Sanofi Recent Developments
- Table 58: Global Pulmonary Hypertension Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 59: Global Pulmonary Hypertension Drug Sales by Region (2021-2026) & (W Units)
- Table 60: Global Pulmonary Hypertension Drug Sales Market Share by Region (2021-2026)
- Table 61: Global Pulmonary Hypertension Drug Sales by Region (2027-2032) & (W Units)
- Table 62: Global Pulmonary Hypertension Drug Sales Market Share by Region (2027-2032)
- Table 63: Global Pulmonary Hypertension Drug Revenue by Region (2021-2026) & (US\$ Million)
- Table 64: Global Pulmonary Hypertension Drug Revenue Market Share by Region (2021-2026)
- Table 65: Global Pulmonary Hypertension Drug Revenue by Region (2027-2032) & (US\$ Million)
- Table 66: Global Pulmonary Hypertension Drug Revenue Market Share by Region (2027-2032)
- Table 67: North America Pulmonary Hypertension Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 68: North America Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units)
- Table 69: North America Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units)
- Table 70: North America Pulmonary Hypertension Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 71: North America Pulmonary Hypertension Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 72: Europe Pulmonary Hypertension Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 73: Europe Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units)
- Table 74: Europe Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units)
- Table 75: Europe Pulmonary Hypertension Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 76: Europe Pulmonary Hypertension Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 77: Asia Pacific Pulmonary Hypertension Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 78: Asia Pacific Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units)
- Table 79: Asia Pacific Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units)
- Table 80: Asia Pacific Pulmonary Hypertension Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 81: Asia Pacific Pulmonary Hypertension Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 82: South America Pulmonary Hypertension Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 83: South America Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units)
- Table 84: South America Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units)
- Table 85: South America Pulmonary Hypertension Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 86: South America Pulmonary Hypertension Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 87: Middle East and Africa Pulmonary Hypertension Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 88: Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units)
- Table 89: Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units)
- Table 90: Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 91: Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 92: Global Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units)
- Table 93: Global Pulmonary Hypertension Drug Sales by Type (2027-2032) & (W Units)
- Table 94: Global Pulmonary Hypertension Drug Sales Market Share by Type (2021-2026)
- Table 95: Global Pulmonary Hypertension Drug Sales Market Share by Type (2027-2032)
- Table 96: Global Pulmonary Hypertension Drug Revenue by Type (2021-2026) & (US\$ Million)
- Table 97: Global Pulmonary Hypertension Drug Revenue by Type (2027-2032) & (US\$ Million)
- Table 98: Global Pulmonary Hypertension Drug Revenue Market Share by Type (2021-2026)
- Table 99: Global Pulmonary Hypertension Drug Revenue Market Share by Type (2027-2032)
- Table 100: Global Pulmonary Hypertension Drug Price by Type (2021-2026) & (US\$/Unit)
- Table 101: Global Pulmonary Hypertension Drug Price by Type (2027-2032) & (US\$/Unit)
- Table 102: Global Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units)
- Table 103: Global Pulmonary Hypertension Drug Sales by Application (2027-2032) & (W Units)
- Table 104: Global Pulmonary Hypertension Drug Sales Market Share by Application (2021-2026)
- Table 105: Global Pulmonary Hypertension Drug Sales Market Share by Application (2027-2032)
- Table 106: Global Pulmonary Hypertension Drug Revenue by Application (2021-2026) & (US\$ Million)
- Table 107: Global Pulmonary Hypertension Drug Revenue by Application (2027-2032) & (US\$ Million)
- Table 108: Global Pulmonary Hypertension Drug Revenue Market Share by Application (2021-2026)
- Table 109: Global Pulmonary Hypertension Drug Revenue Market Share by Application (2027-2032)
- Table 110: Global Pulmonary Hypertension Drug Price by Application (2021-2026) & (US\$/Unit)

- Table 111: Global Pulmonary Hypertension Drug Price by Application (2027-2032) & (US\$/Unit)
- Table 112: Key Raw Materials
- Table 113: Raw Materials Key Suppliers
- Table 114: Pulmonary Hypertension Drug Distributors List
- Table 115: Pulmonary Hypertension Drug Customers List
- Table 116: Pulmonary Hypertension Drug Industry Trends
- Table 117: Pulmonary Hypertension Drug Industry Drivers
- Table 118: Pulmonary Hypertension Drug Industry Restraints
- Table 119: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Pulmonary Hypertension Drug Product Image
- Figure 5: Global Pulmonary Hypertension Drug Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Pulmonary Hypertension Drug Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Pulmonary Hypertension Drug Sales (2021-2032) & (W Units)
- Figure 8: Global Pulmonary Hypertension Drug Average Price (US\$/Unit) & (2021-2032)
- Figure 9: IK-3001 Product Image
- Figure 10: Riociguat Product Image
- Figure 11: Sildenafil Citrate IMD Product Image
- Figure 12: SAR-407899 Product Image
- Figure 13: IK-7002 Product Image
- Figure 14: Others Product Image
- Figure 15: Clinic Product Image
- Figure 16: Hospital Product Image
- Figure 17: Others Product Image
- Figure 18: Global Pulmonary Hypertension Drug Revenue Share by Manufacturers in 2025
- Figure 19: Global Manufacturers of Pulmonary Hypertension Drug, Manufacturing Sites & Headquarters
- Figure 20: Global Top 5 and 10 Pulmonary Hypertension Drug Players Market Share by Revenue in 2025
- Figure 21: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 22: Global Pulmonary Hypertension Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 23: Global Pulmonary Hypertension Drug Sales by Region in 2025
- Figure 24: Global Pulmonary Hypertension Drug Revenue by Region in 2025
- Figure 25: North America Pulmonary Hypertension Drug Market Size by Country in 2025
- Figure 26: North America Pulmonary Hypertension Drug Sales Market Share by Country (2021-2032)
- Figure 27: North America Pulmonary Hypertension Drug Revenue Market Share by Country (2021-2032)
- Figure 28: United States Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 29: Canada Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 30: Mexico Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 31: Europe Pulmonary Hypertension Drug Market Size by Country in 2025
- Figure 32: Europe Pulmonary Hypertension Drug Sales Market Share by Country (2021-2032)
- Figure 33: Europe Pulmonary Hypertension Drug Revenue Market Share by Country (2021-2032)
- Figure 34: Germany Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: France Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: U.K. Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Italy Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Russia Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Spain Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Netherlands Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Switzerland Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Sweden Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: Poland Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: Asia Pacific Pulmonary Hypertension Drug Market Size by Country in 2025
- Figure 45: Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Country (2021-2032)
- Figure 46: Asia Pacific Pulmonary Hypertension Drug Revenue Market Share by Country (2021-2032)
- Figure 47: China Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Japan Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: South Korea Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: India Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Australia Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Taiwan Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 53: Southeast Asia Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: Southeast Asia Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 55: South America Pulmonary Hypertension Drug Market Size by Country in 2025
- Figure 56: South America Pulmonary Hypertension Drug Sales Market Share by Country (2021-2032)
- Figure 57: South America Pulmonary Hypertension Drug Revenue Market Share by Country (2021-2032)
- Figure 58: Brazil Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Argentina Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 60: Chile Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 61: Middle East and Africa Pulmonary Hypertension Drug Market Size by Country in 2025
- Figure 62: Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Country (2021-2032)
- Figure 63: Middle East and Africa Pulmonary Hypertension Drug Revenue Market Share by Country (2021-2032)
- Figure 64: Egypt Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: South Africa Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: Israel Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: Türkiye Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 68: GCC Countries Pulmonary Hypertension Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 69: Global Pulmonary Hypertension Drug Sales Market Share by Type (2021-2032)
- Figure 70: Global Pulmonary Hypertension Drug Revenue Market Share by Type (2021-2032)
- Figure 71: Global Pulmonary Hypertension Drug Price (US\$/Unit) by Type (2021-2032)
- Figure 72: Global Pulmonary Hypertension Drug Sales Market Share by Application (2021-2032)
- Figure 73: Global Pulmonary Hypertension Drug Revenue Market Share by Application (2021-2032)
- Figure 74: Global Pulmonary Hypertension Drug Price (US\$/Unit) by Application (2021-2032)
- Figure 75: Pulmonary Hypertension Drug Value Chain
- Figure 76: Pulmonary Hypertension Drug Production Mode & Process
- Figure 77: Direct Comparison with Distribution Share
- Figure 78: Distributors Profiles
- Figure 79: Pulmonary Hypertension Drug Industry Opportunities and Challenges